SCHEMBL16076223

SCHEMBL16076223

CCCCn1c(=O)c2c(nc(CCCOCC)n2Cc2ccc(Cl)cc2)n(C)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.53
▸ TRPC4 Q9UBN4 2/20 0.51
▸ TRPC5 Q9UL62 2/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ TSHR P16473 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.48
▸ NPSR1 Q6W5P4 4/20 0.48
▸ HTT P42858 1/20 0.48
▸ RAB9A P51151 1/20 0.47
▸ TRPC1 P48995 1/20 0.47
▸ LMNA P02545 2/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ TP53 P04637 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16068298 0.93 TRPC5 (0.60) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL18833941 0.90 TRPC4 (0.47) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL16076222 0.87 TRPC5 (0.60) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL16028111 0.84 P2RX3 (0.48) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL18835260 0.84 TRPC4 (0.51) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL16028784 0.82 TRPC5 (0.64) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL16028393 0.82 TRPC5 (0.66) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL16076248 0.81 TRPC5 (0.67) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL18834872 0.81 TRPC5 (0.65) MAPTTRPC4TRPC5KCNH2TSHR
SCHEMBL16076245 0.81 SMN1; SMN2 (0.60) MAPTTRPC4TRPC5KCNH2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969736-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, INC. (US) 2018-05-15 — — US disclosed
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-26 — — US disclosed
US-20160237089-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-08-18 — — US disclosed
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof TRPC5, TRPC7, TRPC4 MAPT 2951/4885TRPC4 3/4885TRPC5 1/4885
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 MAPT 2951/4885TRPC4 3/4885TRPC5 1/4885
US-20160237089-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 MAPT 2951/4885TRPC4 3/4885TRPC5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback